Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22048336 | 1.00 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL13835639 | 1.00 | — | — | |
| SCHEMBL24511688 | 0.97 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL15321 | 0.97 | — | — | |
| SCHEMBL18946139 | 0.97 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL21057351 | 0.94 | HTR6 (0.54) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL21422636 | 0.94 | HTR6 (0.54) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL22216666 | 0.94 | HTR6 (0.54) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL60131 | 0.94 | HTR6 (0.54) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 | |
| SCHEMBL1828721 | 0.94 | HTR6 (0.54) | L3MBTL3L3MBTL1CYP2D6CYP2C19HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-3133058-B1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10266476-B2 | (Meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-10065916-B2 | Method for producing (meth)acrylate | TOAGOSEI CO., LTD (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20180237629-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180187026-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180171038-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180105483-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | TOAGOSEI CO., LTD. (JP) | 2018-04-19 | — | — | US | disclosed |
| EP-3281933-A1 | (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2018-02-14 | — | — | EP | disclosed |
| EP-3269700-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | Toagosei Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| EP-3133058-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| US-8506913-B2 | Acidic gas absorbent, acidic gas removal device, and acidic gas removal method | KABUSHIKI KAISHA TOSHIBA (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2554243-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | Kabushiki Kaisha Toshiba (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120294785-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | L3MBTL3 3592/4885L3MBTL1 2869/4885CYP2D6 57/4885 |
| US-10065916-B2 | Method for producing (meth)acrylate | MMAB, ADH5, ADH1A | L3MBTL3 3046/4885L3MBTL1 3412/4885CYP2D6 957/4885 |
| US-20180171038-A1 | CURABLE COMPOSITION | KAT2B, ACR, GK | L3MBTL3 3584/4885L3MBTL1 3527/4885CYP2D6 4795/4885 |
| US-20180187026-A1 | CURABLE COMPOSITION | AZI2, KAT2A, KAT2B | L3MBTL3 3167/4885L3MBTL1 3066/4885CYP2D6 4844/4885 |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | MMAB, AMD1, ADH5 | L3MBTL3 1752/4885L3MBTL1 1501/4885CYP2D6 1416/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | L3MBTL3 3480/4885L3MBTL1 3189/4885CYP2D6 4824/4885 |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | MMAB, AMD1, ADH5 | L3MBTL3 1752/4885L3MBTL1 1501/4885CYP2D6 1416/4885 |
| US-20180105483-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | MMAB, ADH5, ADH1A | L3MBTL3 3046/4885L3MBTL1 3412/4885CYP2D6 957/4885 |
| US-10266476-B2 | (Meth)acrylate manufacturing method | MMAB, PAM, MAT2B | L3MBTL3 3148/4885L3MBTL1 3978/4885CYP2D6 2408/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | L3MBTL3 2648/4885L3MBTL1 2368/4885CYP2D6 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.